Page Synopsis: Hormone replacement therapy is controversial and potentially dangerous both in potentially limiting the body's production of endegenous hormones, and in terms of possibly developing cancer.

 

HRT treatment makes sense as CFS sufferers hormone levels when PROPERLY tested and evaluated are significantly low (or high in the wrong departments.

 

For full report on CFS symptoms, meaures and oddities, see the 'Consistent Abnormalities' page at the full report https://bra.in/8pK4xB

Skill Level  3

Relevance:5 Technical Level:3

Discuss this page with your medical practitioner. If you have the financial means, consider discussing with a non alopathic practioner as well

page 5 CFS > HORMONE REPLACEMENT THERAPY

page 4

page 6

Full HRT TRT report https://bra.in/4jY3D2

Full Report Clearfield Panhypopituitarism and TBI (right click and 'save as'

Diagnosis and Treatment of Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysfunction in Patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM). Journal Of Chronic Fatigue Syndrome https://sci-hubtw.hkvisa.net

 

Physiologic replacement of cortisol at doses of 5-15 mg/day have been shown to be safe, with little or no as.sociated risk, and have the potential for significant clinical benefit. Cortisol treatment carries significantly less risk and a greater potential for benefit than treatments considered to be the standard of care in the treatment of CFS/FM, including antidepressants, muscle relaxants and narcotics.

 

The current evidence supports the use of physiologic doses of cortisol as an appropriate component ofa multi-system treatment protocol for CFS and FM, and a therapeutic trial of cortisol should be considered in the majority of these patients, especially those with signs or symptoms consistent with adrenal dysfunction, low blood pressure and/or serum levels that are low or in the low normal range

 

From: Clearfield Panhypopituitarism and TBI

http://www.nevadaosteopathic.org/attachments/article/33/Clearfield%20Panhypopituitarism%20and%20TBI.pdf

 

• 80% of TBI Injuries are mild without LOC

• Acute hormone deficiencies occur in 56% of Head Injuries

• 36% continue on to Chronic Hormone Deficiency

• Psychotropic Meds Mask Symptoms

• Psychotropic meds do not address underlying cause

• Plan: Replace Deficient Hormones to Physiologic Levels

please wait for document to load, use sidebar to scroll down page and 'Previous' and 'Next' buttons to advance pages

click here to read the entire document as a continuous file (or if document takes too long to load)

   Page: /

Full presentation PanhypopituitarismandTBI ***

Prescription medications that I have taken for CFS https://livingwithchronicfatiguesyndrome.wordpress.com/page/10

 

'T3– I had TSH levels of 4.1 and was prescribed T3. What is considered to be a high TSH level is controversial as some doctors would consider 4.1 high and other doctors would consider this normal. Taking T3 is the single worst tablet that has affected my CFS. After taking T3 I became extremely sensitive to sound, more anxious than I previously was and became more fatigued. Dr Cheney claims that T3 is the worst hormone that you can give to someone with CFS'

  • HGH (Growth Hormone) and                      click to open                             click again to close
    Growth Hormone Deficiency (GHD)

     

    GH deficiency as the most common pituitary defect after TBI: clinical implications. PubMed NCBI

     

    Recent studies have demonstrated that hypopituitarism, and in particular growth hormone deficiency (GHD), is common among survivors of traumatic brain injury (TBI) tested several months or years following head trauma. In addition, it has been shown that posttraumatic neuroendocrine abnormalities occur early and with high frequency. These findings may have significant implications for the recovery and rehabilitation of patients with TBI. The subjects at risk are those who have suffered moderateto severe head trauma although mild intensity trauma may precede hypopituitarism also. Particular attention should be paid to this problem in children and adolescents. GH deficiency is very common in TBI, particularly isolated GHD. For the assessment of the GHIGF axis in TBI patients, plasma IGFI concentrations plus GH response to a provocative test is mandatory. Growth retardation secondary to GHD is a predominant feature of GHD after TBI in children. Clinical features of adult GHD are variable and in most obesity is present. Neuropsychological examinations of patients with TBI show that a significant portion of variables like attention, concentration, learning, memory, conceptual thinking, problem solving and language are impaired in patients with TBI. In the few case reports described, hormone replacement therapy in hormone deficient headinjured patients resulted in major neurobehavioral improvements. Improvements in mentalwell being and cognitive function with GH replacement therapy in GHD adults have been reported. The effect of GH replacement in posttraumatic GHD needs to be examined in randomized controlled studies.

     

     

     

    From: Chronic cognitive sequelae after traumatic brain injury are not related to growth hormone deficiency in adults. PubMed NCBI

     

    GHD persists long after the TBI, independently of trauma severity and age at traumatic event. GH secretion is more sensitive to TBI than other pituitary hormones.

     

     

     

    From: Clearfield Panhypopituitarism and TBI http://www.nevadaosteopathic.org/attachments/article/33/Clearfield%20Panhypopituitarism%20and%20TBI.pdf

     

    Growth Hormone Deficiency (GHD) – First and most common deficiency – Acute Injury Incidence rate: 20%. – 12 month follow up rate increases to 3540% of survivors.

     

     

     

    TBI with GHD • Rapid weight gain • Excessive anxiety • Depression along • Deficits in: – Attention – Executive Functioning – Memory – Emotion – Cognition – Mood Anxiety/Depression • Poor overall physical health and quality of life

     

     

     

    GH Replacement – Improvements in: • Cardiovascular Risk – Reduces IL6, Il1, cRP, Homocysteine • Concentration • Memory • Depression • Anxiety • Fatigue • Lean body mass • Lumbar vertebral bone density • 14.4 % decrease in adipose tissue mass • Skin thickness

     

     

     

    GH Deficiency Associated w Cognitive Dysfunction and “Atypical Depression”

     

     

     

    Correction of GHD : Tempers: Intensity of Outbursts Hostility Paranoid Ideation Anxiety, Phobia Somatization Obsessive Compulsive S/S Improves: Verbal and NonVerbal Memory Cognition Mental Alertness Work Capacity

     

     

     

    GH Lab Values and Rx. Lab Values: GH 5.0 ng/ml IGF1 200 ng/ml IGFBP3 4000 ng/ml RX: Injectables: HGH 0.81.2 IU/day SQ57 IU day/wk. Semorelean w or W/O GNRH 2 or 6 (2 causes nausea, 6 hunger) Peptide CJC 1295 with DAC 0.52.0 mg q. week (Can cause hot flash for 5 15 minutes ) Oral Spray: HGH Spray (Homeopathic) Secretropin, Dynotropin

     

     

    Case study Olivia G.

     

    Diagnosis: Treatment Resistant Depression

     

    Growth Hormone

     

    (Morning Lab Draw)

     

     

     

    Olivia                                     Median

     

    Growth Hormone             0.6 ng/ml                             5 ng/ml

     

    IGF1                                78 ng/ml                              > 200 ng/ml

     

    IGFBP3                              2950 ng/ml                         > 4000 ng/ml

     

     

     

    IGF1 as proxy

     

    IGFBP 3 logarithmic relation to GH Pulse

     

    Estrogen and Quercetin can stimulate IGf BP 3

     

  •                                                                                                                          click to scroll up and close

click

click for full size, click 'x' button to close

Topics associated with HGH

To view this page on full report, click https://bra.in/8pyZDa

 

page 5 CFS > HORMONE REPLACEMENT THERAPY

page 4

page 6

sitemap click links below

Click 1

Click 2

Click 3